SanjayGoelMD, MS

PubMed

• 28 citations
  Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes
  Raymond U. Osarogiagbon, Helmneh M. Sineshaw, Joseph M. Unger, Ana Acuna-Villaorduna, Sanjay Goel
  American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2021-04-08
• 58 citations
  Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-Refractory Advanced Solid Tumors
  Filip Janku, Halle H. Zhang, Abdul Mohammad Pezeshki, Sanjay Goel, Ravi Murthy
  Clinical Cancer Research. 2021-01-01
• 19 citations
  Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open...
  Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, Tanya B Dorff, William Kelly
  The Lancet. Oncology. 2022-07-01

Journal Articles

• Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case For Prophylaxis.  
  Swami U, Goel S, Mani S, Curr Drug Targets, 4/15/2013
• Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.  
  Aparo S, Goel S, Crit Rev Oncol Hematol, 7/1/2012
• Eribulin-A review of preclinical and clinical studies.  
  Swami U, Chaudhary I, Ghalib MH, Goel S, Crit Rev Oncol Hematol, 2/1/2012
• Reovirus: A Targeted Therapeutic – Progress and Potential.  
  Maitra R, Ghalib MH, Goel S, Mol Cancer Res, 1/1/2012
• Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review.  
  Merla A, Goel S, Chemotherapy Research and Practice, 1/1/2012
• Safety, Pharmacokinetics and activity of EZN-2208, a Novel Conjugate of Polyethylene Glycol and SN38, in patients with advanced malignancies.  
  Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M, Cancer, 1/1/2012
• PTEN Gene Expression and Mutations in The PIK3CA Gene as Predictors of Clinical Benefit to Anti Epidermal Growth Factor Receptor Antibody Therapy In Patients With KRAS...  
  Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S, Clin Colorectal Cancer, 1/1/2012
• Multicenter Phase II Study of Trabectedin in Patients with Metastatic Castration Resistant Prostate Cancer.  
  Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR, Ann Oncol, 1/1/2012
• Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Accepted. Cancer Chemotherapy and Pharmacology.  
  Lam ET, Goel S, Schaaf LJ, Cropp G, Hannah AL, Zhou Y, McCracken B, Haley BI, Johnson RG, Mani S, Villalona-Calero MA, Cancer Chemother Pharmacol, 1/1/2012
• Metastatic Colorectal Cancer: A Paradigm for Personalized Medicine  
  Goel S, 2/1/2011
• Revised TNM staging for colorectal cancer: Did we miss the golden opportunity to do right by the staging?  
  Nayak J, Goel S, Clin Colorectal Cancer, 1/1/2011
• Therapeutic Oligonucleotides--The Road Not Taken.  
  Stein CA, Goel S, Clin Colorectal Cancer, 1/1/2011
• Intestinal epithelial-specific PTEN inactivation results in tumor formation.  
  Byun DS, Ahmed N, Nasser S, Shin J, Al-Obaidi S, Goel S, Corner GA, Wilson AJ, Flanagan DJ, Williams DS, Augenlicht LH, Vincan E, Mariadason JM, Am J Physiol Gastrointest Liver Physiol, 1/1/2011
• Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gen...  
  Cancer Res, 1/1/2010
• Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors.  
  Gollamudi R, Ghalib MH, Desai K, Chaudhary I, Wong B, Einstein M. Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S, Invest New Drugs, 1/1/2010
• Oxaliplatin Resistance Induced by ERCC1 Upregulation is Abrogated by siRNA Mediated Gene Silencing in Human Colorectal Cancer Cells.  
  Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S, Anticancer Research, 1/1/2010
• Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-acetic acid) to Docetaxel in Castration-Refractory Metastatic Prostate Cancer.  
  Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P, Clin Cancer Res, 1/1/2010
• Phase II Study of Paclitaxel plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma.  
  Lam A, Sparano JA, Vinciguerra V, Ocean A, Christos P, Hochster H, Camacho F, Goel S, Mani S, Kaubisch A, Am J Clin Oncol, 1/1/2010
• An A13 Repeat within the 3’-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) is frequently mutated in Microsatellite Instability Colon Cancers and is Ass...  
  Yuan Z, Shin J, Wilson A, Goel S, Ling Y-H, Ahmed N, Dopeso H, Jhawer M, Nasser S, Montagna C. Fordyce K, Augenlicht LH, Aaltonen LA, Arango D, Weber TK, Mariadason JM, Cancer Res, 1/1/2009
• A Phase I Study Of Eribulin Mesylate (E7389), A Novel Inhibitor Of Microtubule Dynamics, In Patients With Advanced Solid Tumors.  
  Goel S, Mita A, Wong N, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH, Clin Cancer Res, 1/1/2009
• Bioequivalence of a new oral topotecan formulation relative to the current topotecan formulation in patients with advanced solid tumors.  
  Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, Voesta EE, Burris H, Schellens HMS, Int J Clin Pharmacol Ther, 1/1/2009
• Oxaliplatin: Preclinical perspectives on the mechanisms of action, response and resistance.  
  Seetharam RN, Sood A, Goel S., Ecancer Medical Science, 1/1/2009
• Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.  
  Mani S, Ghalib M, Chaudhary I, Goel S, Expert Opin Drug Metab Toxicol, 1/1/2009
• The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone, a first in class epothilone B analog in late phase clinical development.  
  Goel S, Cohen M, Comezoglu N, Perrin L, Andre F, Jayabalan D, Iacono L, Comprelli A, Ly VT, Zhang D, Xu C, W. Humphreys G, McDaid H, Goldberg G, Horwitz SB, Mani S, Clin Cancer Res, 1/1/2008
• Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism.  
  Gollamudi R, Gupta D, Goel S, Mani S, Curr Drug Metab, 1/1/2008
• Join now to see all

Abstracts/Posters

• Tumor Biology
  Goel S, 47th Annual Meeting of the American Society of Clinical Oncology, 6/1/2011
• “PIK3CA/PTEN mutation status predicts response of the colon cancer cells to the EGFR inhibitor cetuximab”
  Goel S, Jhawer M, Wilson AJ, et al, 2007 ECOG Young Investigators Symposium in Fort Lauderdale, FL, 1/1/2007
• Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamcis of Ixabepilone.
  Goel S, Goldberg G, Iacono L, et al, ASCO Annual Meeting Proceedings Part I, 6/20/2006
• First-in-human Phase 1 Trial of a Novel Epothilone, KOS-1584.
  Villalona-Calero M, Goel S, et al, Annual Meeting Proceedings Part I, 6/20/2006
• Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamcis of Ixabepilone.
  Goel S, Goldberg G, Iacono L, et al, Journal of Clinical Oncology, 1/1/2006
• First-in-human Phase 1 Trial of a Novel Epothilone, KOS-1584.
  Villalona-Calero M, Goel S, et al, Journal of Clinical Oncology, 1/1/2006
• “Phase I study monitoring extracellular PKA (ECPKA) in a continuous intravenous infusion (CIV) with GEM® 231, a second generation antisense oligonucleotide targeted ag...
  Goel S, Cho-Chung YS, Nesterova M, et al, Glaxo Smith-Kline National Oncology Fellows Forum. Feb 28-Mar 3, 2002, 2/28/2002
• “First Human Experience with GEM® 231, a second generation antisense oligonucleotide targeted against PKA R1 Alpha. Preliminary proof of concept using a novel assay fo...
  Goel S, Cho-Chung YS, Nesterova M, et al, Montefiore Young Investigators Symposium, 2/8/2002
• “Phase I Clinical Trial of Irinotecan with Oral Capecitabine in Patients with Gastrointestinal and other Solid Malignancies”
  Goel S, Rajdev L, Jhawer M, et a, ECOG Young Investigators Symposium held at Miami Beach, FL, Nov 9-12, 2001, 11/9/2001
• Join now to see all

Lectures

• Assessing Response to Therapy: Radiographic Response Criteria Review 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
• Colorectal Cancer: Updates and Future Directions 
  Department of Pathology, Assam Medical College, Dibrugah, Assam, India - 10/1/2010
• Updates in Colorectal Cancer 
  Grand Rounds, Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine - 12/1/2006
• Chemotherapy for cancer of the urinary bladder 
  Grand Rounds, Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine - 12/1/2004
• Join now to see all